Related Experiment Video
Updated: Jun 2, 2026
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
How should hypomagnesaemia be investigated and treated?
1Department of Endocrinology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
Clinical Endocrinology
|May 17, 2011
Summary
Hypomagnesaemia, or low magnesium levels, affects 2.5-15% of people. Drug-induced cases, especially from proton pump inhibitors, are rising, requiring specific treatment strategies for symptomatic patients.
Area of Science:
- Endocrinology
- Nephrology
- Pharmacology
Background:
- Hypomagnesaemia is a common condition with a prevalence of 2.5% to 15% in the general population.
- Causes include inadequate intake, increased losses (GI/renal), or intracellular shifts.
- Drug-induced hypomagnesaemia, particularly from proton pump inhibitors (PPIs), is increasingly recognized.
Observation:
- Most hypomagnesaemia cases are asymptomatic.
- Symptomatic magnesium depletion often co-occurs with hypokalemia, hypocalcemia, and metabolic acidosis.
- Clinical manifestations primarily involve neuromuscular, cardiovascular, and metabolic systems.
Findings:
- Symptomatic hypomagnesaemia presents with diverse clinical features.
- The association between PPI use and hypomagnesaemia is a significant clinical observation.
Implications:
- Urgent intravenous magnesium is recommended for symptomatic hypomagnesaemia.
- Oral magnesium replacement is suitable for asymptomatic individuals.
- Increased awareness of drug-induced hypomagnesaemia is crucial for patient management.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...